Boryung Corporation (003850.KS)
KRW 10260.0
(-3.39%)
KRW 10260.0
(-3.39%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 859.62 Billion KRW | 13.04% |
| 2022 | 760.47 Billion KRW | 21.23% |
| 2021 | 627.27 Billion KRW | 11.64% |
| 2020 | 561.86 Billion KRW | 7.17% |
| 2019 | 524.26 Billion KRW | 13.87% |
| 2018 | 460.4 Billion KRW | 8.91% |
| 2017 | 422.72 Billion KRW | 3.32% |
| 2016 | 409.14 Billion KRW | 1.94% |
| 2015 | 401.35 Billion KRW | 11.64% |
| 2014 | 359.49 Billion KRW | 9.84% |
| 2013 | 327.27 Billion KRW | 4.87% |
| 2012 | 312.07 Billion KRW | 1.32% |
| 2011 | 308 Billion KRW | 2.34% |
| 2010 | 300.95 Billion KRW | 12.36% |
| 2009 | 267.84 Billion KRW | 19.97% |
| 2008 | 223.25 Billion KRW | 13.04% |
| 2007 | 197.5 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 255.56 Billion KRW | 9.4% |
| 2024 Q3 | 271.03 Billion KRW | 6.05% |
| 2024 Q1 | 233.6 Billion KRW | 1.02% |
| 2023 Q4 | 231.23 Billion KRW | 11.0% |
| 2023 Q1 | 203.81 Billion KRW | 1.16% |
| 2023 Q3 | 208.31 Billion KRW | -3.67% |
| 2023 FY | 859.62 Billion KRW | 13.04% |
| 2023 Q2 | 216.25 Billion KRW | 6.11% |
| 2022 Q2 | 182.47 Billion KRW | 2.17% |
| 2022 FY | 760.47 Billion KRW | 21.23% |
| 2022 Q4 | 201.46 Billion KRW | 1.79% |
| 2022 Q3 | 197.92 Billion KRW | 8.47% |
| 2022 Q1 | 178.6 Billion KRW | 7.82% |
| 2021 Q2 | 150.25 Billion KRW | 4.39% |
| 2021 Q1 | 143.93 Billion KRW | 4.02% |
| 2021 FY | 627.27 Billion KRW | 11.64% |
| 2021 Q3 | 167.43 Billion KRW | 11.44% |
| 2021 Q4 | 165.64 Billion KRW | -1.07% |
| 2020 Q1 | 134.21 Billion KRW | -3.41% |
| 2020 FY | 561.86 Billion KRW | 7.17% |
| 2020 Q3 | 154.77 Billion KRW | 15.08% |
| 2020 Q4 | 138.37 Billion KRW | -10.6% |
| 2020 Q2 | 134.49 Billion KRW | 0.21% |
| 2019 Q2 | 127.26 Billion KRW | 7.18% |
| 2019 FY | 524.26 Billion KRW | 13.87% |
| 2019 Q1 | 118.73 Billion KRW | 5.38% |
| 2019 Q3 | 139.32 Billion KRW | 9.47% |
| 2019 Q4 | 138.94 Billion KRW | -0.27% |
| 2018 Q4 | 112.68 Billion KRW | -7.3% |
| 2018 Q3 | 121.55 Billion KRW | 6.19% |
| 2018 FY | 460.4 Billion KRW | 8.91% |
| 2018 Q2 | 114.46 Billion KRW | 2.48% |
| 2018 Q1 | 111.69 Billion KRW | 19.0% |
| 2017 Q3 | 120.06 Billion KRW | 10.2% |
| 2017 Q4 | 93.86 Billion KRW | -21.82% |
| 2017 FY | 422.72 Billion KRW | 3.32% |
| 2017 Q1 | 99.85 Billion KRW | 2.21% |
| 2017 Q2 | 108.94 Billion KRW | 9.11% |
| 2016 FY | 409.14 Billion KRW | 1.94% |
| 2016 Q2 | 105.3 Billion KRW | 18.51% |
| 2016 Q3 | 117.28 Billion KRW | 11.38% |
| 2016 Q4 | 97.69 Billion KRW | -16.71% |
| 2016 Q1 | 88.85 Billion KRW | -12.61% |
| 2015 Q4 | 101.67 Billion KRW | -9.26% |
| 2015 Q2 | 100.73 Billion KRW | 15.92% |
| 2015 Q1 | 86.89 Billion KRW | -3.07% |
| 2015 FY | 401.35 Billion KRW | 11.64% |
| 2015 Q3 | 112.04 Billion KRW | 11.23% |
| 2014 Q1 | 76.36 Billion KRW | -11.07% |
| 2014 Q3 | 103.63 Billion KRW | 15.36% |
| 2014 Q4 | 89.65 Billion KRW | -13.49% |
| 2014 Q2 | 89.83 Billion KRW | 17.63% |
| 2014 FY | 359.49 Billion KRW | 9.84% |
| 2013 Q2 | 83.72 Billion KRW | 26.23% |
| 2013 Q4 | 85.87 Billion KRW | -6.01% |
| 2013 FY | 327.27 Billion KRW | 4.87% |
| 2013 Q1 | 66.32 Billion KRW | -13.01% |
| 2013 Q3 | 91.35 Billion KRW | 9.12% |
| 2012 FY | 312.07 Billion KRW | 1.32% |
| 2012 Q1 | 75.84 Billion KRW | 11.32% |
| 2012 Q4 | 76.24 Billion KRW | -8.22% |
| 2012 Q3 | 83.07 Billion KRW | 8.02% |
| 2012 Q2 | 76.91 Billion KRW | 1.41% |
| 2011 Q4 | 68.12 Billion KRW | -18.11% |
| 2011 FY | 308 Billion KRW | 2.34% |
| 2011 Q3 | 83.19 Billion KRW | 2.56% |
| 2011 Q2 | 81.12 Billion KRW | 7.36% |
| 2011 Q1 | 75.55 Billion KRW | 5.29% |
| 2010 Q2 | 80.23 Billion KRW | 11.57% |
| 2010 Q1 | 71.91 Billion KRW | 13.42% |
| 2010 FY | 300.95 Billion KRW | 12.36% |
| 2010 Q4 | 71.76 Billion KRW | -6.86% |
| 2010 Q3 | 77.04 Billion KRW | -3.97% |
| 2009 Q3 | 68.79 Billion KRW | -4.09% |
| 2009 Q1 | 63.9 Billion KRW | 11.58% |
| 2009 Q2 | 71.73 Billion KRW | 12.25% |
| 2009 Q4 | 63.4 Billion KRW | -7.84% |
| 2009 FY | 267.84 Billion KRW | 19.97% |
| 2008 Q4 | 57.27 Billion KRW | 1.67% |
| 2008 Q1 | 50.96 Billion KRW | -2.32% |
| 2008 Q2 | 58.68 Billion KRW | 15.15% |
| 2008 FY | 223.25 Billion KRW | 13.04% |
| 2008 Q3 | 56.33 Billion KRW | -4.0% |
| 2007 FY | 197.5 Billion KRW | 0.0% |
| 2007 Q2 | 47.75 Billion KRW | -0.89% |
| 2007 Q4 | 52.17 Billion KRW | 5.62% |
| 2007 Q1 | 48.17 Billion KRW | 0.0% |
| 2007 Q3 | 49.39 Billion KRW | 3.45% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -526.505% |
| Dong-A Socio Holdings Co., Ltd. | 1132 Billion KRW | 24.062% |
| Ildong Holdings Co., Ltd. | 638.44 Billion KRW | -34.643% |
| HANDOK Inc. | 522.74 Billion KRW | -64.446% |
| Kukje Pharma Co., Ltd. | 135.37 Billion KRW | -535.007% |
| Yuhan Corporation | 1858.98 Billion KRW | 53.758% |
| Dong-A ST Co., Ltd. | 663.98 Billion KRW | -29.466% |
| SAMSUNG PHARM. Co., LTD. | 51.95 Billion KRW | -1554.557% |
| Hanmi Pharm. Co., Ltd. | 1490.88 Billion KRW | 42.341% |
| Hanall Biopharma Co.,Ltd | 134.9 Billion KRW | -537.185% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | -131.994% |
| Dong Sung Bio Pharm.Co.,Ltd. | 88.59 Billion KRW | -870.302% |
| MYUNGMOON Pharm co.,Ltd | 169.56 Billion KRW | -406.952% |
| Hana Pharm Co., Ltd. | 224.45 Billion KRW | -282.98% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -526.505% |
| Ilsung Pharmaceuticals Co., Ltd. | 78.05 Billion KRW | -1001.332% |
| REYON Pharmaceutical Co., Ltd. | 151.07 Billion KRW | -469.02% |
| Aprogen pharmaceuticals,Inc. | 87.36 Billion KRW | -883.963% |
| JW Holdings Corporation | 928.07 Billion KRW | 7.375% |
| Ildong Pharmaceutical Co., Ltd. | 600.75 Billion KRW | -43.09% |
| Chong Kun Dang Pharmaceutical Corp. | 1669.4 Billion KRW | 48.507% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | -14.842% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | -329.322% |
| Hyundai Pharmaceutical Co., Ltd. | 180.76 Billion KRW | -375.555% |
| Samil Pharmaceutical Co.,Ltd | 196.34 Billion KRW | -337.812% |
| Jeil Pharmaceutical Co.,Ltd | 726.39 Billion KRW | -18.342% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -526.505% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1514.45 Billion KRW | 43.239% |
| Daewoong pharmaceutical Co.,Ltd | 1375.32 Billion KRW | 37.497% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | -14.842% |
| Yuhan Corporation | 1858.98 Billion KRW | 53.758% |
| Jeil Pharma Holdings Inc | 794.71 Billion KRW | -8.168% |
| Yungjin Pharm. Co., Ltd. | 234.9 Billion KRW | -265.95% |
| Suheung Co., Ltd. | 594.56 Billion KRW | -44.58% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | -14.842% |
| Samjin Pharmaceuticals Co., Ltd. | 292.12 Billion KRW | -194.263% |
| Korea United Pharm Inc. | 278.94 Billion KRW | -208.172% |
| CKD Bio Corp. | 160.35 Billion KRW | -436.084% |
| Daewon Pharmaceutical Co., Ltd. | 526.95 Billion KRW | -63.132% |
| Dongwha Pharm.Co.,Ltd | 361.1 Billion KRW | -138.052% |
| Whan In Pharm Co.,Ltd. | 230.39 Billion KRW | -273.112% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | -329.322% |
| Chong Kun Dang Holdings Corp. | 879.78 Billion KRW | 2.291% |
| Bukwang Pharmaceutical Co., Ltd. | 125.92 Billion KRW | -582.631% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | -131.994% |
| JW Lifescience Corporation | 206.86 Billion KRW | -315.558% |